氨基甲酸2-丙氧乙基酯 | 69353-09-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 氨基甲酸2-丙氧乙基酯
• 英文名称: carbamic acid-(2-propoxy-ethyl ester)
• 英文别名: Carbamidsaeure-(2-propyloxy-aethylester)；Carbamidsaeure-(2-propoxy-aethylester)；Carbamic acid, (2-propoxyethyl) ester；2-propoxyethyl carbamate
• CAS: 69353-09-9
• 化学式: C₆H₁₃NO₃
• mdl: MFCD01738925
• 分子量: 147.174
• InChiKey: GLRSFSJGWOZGTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES
  申请人：Braun Christoph

  公开号：US20140349848A1

  公开（公告）日：2014-11-27

  The present invention provides fungicidal 4-substituted-3-phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadiazol-5(4H)-one derivatives of formula (I) wherein A represents a pyridyl or thiazole group and X1, Y1 to Y5 represent independently different substituents.

  本发明提供了式（I）的杀真菌4-取代-3- 苯基 [（杂环甲氧基）亚胺]甲基} -1,2,4-噁唑-5（4H）-酮衍生物，其中A代表吡啶基或噻唑基，X1，Y1至Y5分别代表不同的取代基。
• Duocarmycin ADCs showing improved in vivo antitumor activity
  申请人：Byondis B.V.

  公开号：US11382982B2

  公开（公告）日：2022-07-12

  The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

  本发明涉及含杜卡霉素的抗体药物偶联物(ADCs)，用于治疗表达HER2的实体瘤和血液系统恶性肿瘤，尤其是乳腺癌、胃癌、膀胱癌、卵巢癌、肺癌、前列腺癌、胰腺癌、结直肠癌、头颈部鳞状细胞癌或骨肉瘤，以及急性淋巴细胞白血病。特别地，本发明涉及用于治疗HER2免疫组化(IHC)2+或1+且HER2荧光原位杂交(FISH)阴性肿瘤状态的人类实体瘤的含杜卡霉素的ADCs。更有利的是，本发明涉及用于治疗三阴性乳腺癌(TNBC)的含杜卡霉素的ADCs。
• FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2755949B1

  公开（公告）日：2015-10-21
• DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
  申请人：Synthon Biopharmaceuticals B.V.

  公开号：US20190314513A1

  公开（公告）日：2019-10-17

  The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
• US9090600B2
  申请人：——

  公开号：US9090600B2

  公开（公告）日：2015-07-28